MedPath

europrotective effects of L-Carnitine and Fat emulsion in the CVA Ischemic patients

Not Applicable
Completed
Conditions
cerebrovascular accident ischemic.
Cerebrovascular accident NOS
Registration Number
IRCT201510043014N11
Lead Sponsor
Vice chancellor for research, Mazandaran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

CVA ischemic MCA inpatient, admitted during first 24 hours after the onset of symptoms, 21-75 years old
Exclusion criteria: less than 21years old and more than 75 years old, hepatic failure( rise hepatic enzymes >5nl, cirrhosis), treatment by valproate, treatment by hemodialysis, sepsis, ARDS, triglyceride > 400, acute pancreatitis plus hyperlipidemia, plt < 70000, signs and symptoms appearance more than 72 hours before admission, CNS infections, seizure, migraine.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
euron specific enolase: NSE. Timepoint: base, 24hr after admission, 48hr after admission, 7th days after admission. Method of measurement: 5 cc serum plasma.;S100B. Timepoint: base, 24hr after admission, 48hr after admission, 7th days after admission. Method of measurement: 5 cc serum plasma.;Lactate dehydrogenase. Timepoint: base, 24hr after admission, 48hr after admission, 7th days after admission. Method of measurement: 5 cc serum plasma.;Pirovate dehydrogenase. Timepoint: base, 24hr after admission, 48hr after admission, 7th days after admission. Method of measurement: 5 cc serum plasma.
Secondary Outcome Measures
NameTimeMethod
Evaluation neurologic outcomes : Neurologic examination of GCS, cranial nerves, motor nerves, sensory nerves. Timepoint: At admission time and when Discharge from hospital. Method of measurement: Physical examination.
© Copyright 2025. All Rights Reserved by MedPath